Targeting translation: eIF4E as an emerging anticancer drug target

Expert Reviews in Molecular Medicine
Chunwan LuYafei Cai

Abstract

The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

References

Feb 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·D RousseauN Sonenberg
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·H AktasJ A Halperin
Apr 27, 1999·The International Journal of Biochemistry & Cell Biology·S R Kimball
Apr 27, 1999·The International Journal of Biochemistry & Cell Biology·R JagusG N Barber
May 6, 1999·Cellular and Molecular Life Sciences : CMLS·B WeissL W Zhou
Nov 24, 1999·Biochemical and Biophysical Research Communications·T ItoW S May
Jul 19, 2000·Current Biology : CB·T P HerbertC G Proud
Nov 4, 2000·Medicinal Research Reviews·C R WagnerE J McIntee
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·M S NeshatC L Sawyers
Mar 13, 2003·Kidney International·Fu L LuanManikkam Suthanthiran
Dec 4, 2003·Journal of Pharmaceutical Sciences·Rosie Z YuArthur A Levin
Dec 10, 2003·Oncogene·Nicholas M Dean, C Frank Bennett
Apr 7, 2004·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Noriko OshiroKazuyoshi Yonezawa
Apr 20, 2004·Oncogene·Yaël MamaneNahum Sonenberg
Apr 20, 2004·Oncogene·Arrigo De Benedetti, Jeremy R Graff
May 28, 2004·Nature Structural & Molecular Biology·Tobias von der HaarJohn E G McCarthy
Jul 29, 2004·Current Pharmaceutical Design·A PicardiA Afeltra
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda A deGraffenriedManuel Hidalgo
Dec 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alex KentsisKatherine L B Borden
Jan 22, 2005·Seminars in Cell & Developmental Biology·Andrew R Tee, John Blenis
Feb 4, 2005·Nature·Joel D Richter, Nahum Sonenberg
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigScott H Kaufmann
Jul 20, 2005·Journal of Clinical Pharmacology·Chetan S KaryekarRobert O'Dea
Jul 22, 2005·Molecular Cancer·Chunjing WuNiramol Savaraj
Oct 28, 2005·RNA·Alex KentsisKatherine L B Borden
Dec 7, 2005·International Journal of Cancer. Journal International Du Cancer·Daisuke ItoRyuichiro Doi
Jan 7, 2006·Cell Cycle·Amith PannerRussell O Pieper
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Feb 14, 2006·Cell·Stephan WullschlegerMichael N Hall
May 25, 2006·The Journal of Biological Chemistry·Takayuki Murata, Kunitada Shimotohno
Jun 3, 2006·Cancer Research·Donatella Del BufaloMichele Milella

❮ Previous
Next ❯

Citations

Mar 11, 2017·Current Opinion in Oncology·Vidya P RamamurthyVincent C O Njar
Jan 16, 2018·Cancer Biology & Therapy·Zhongyuan GaoXuerong Wang
May 11, 2019·Journal of Cellular Biochemistry·Asiya BatoolKhurshid I Andrabi
Aug 26, 2017·Future Medicinal Chemistry·Ella LinehamSimon J Morley
Aug 12, 2019·Parasitology Research·Filipe Santos Pereira-DutraArnaldo Zaha
Jun 9, 2018·Acta Neuropathologica Communications·Samuel Rivero-HinojosaBrian R Rood
Nov 25, 2020·Investigational New Drugs·Blake A JacobsonRobert A Kratzke
Jan 26, 2021·Analytical Cellular Pathology (Amsterdam)·Jun ZhengYiqiang Zhang
Feb 17, 2021·Journal of Medicinal Chemistry·Angela Fan, Phillip P Sharp
Jun 2, 2020·International Journal of Biological Macromolecules·Jun WangChuanlong Guo
Sep 21, 2021·Cellular and Molecular Life Sciences : CMLS·Alice RomagnoliDaniele Di Marino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.